-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Aigen Investment Management LP Makes New $2.46 Million Investment in Sanofi (NASDAQ:SNY)
Aigen Investment Management LP Makes New $2.46 Million Investment in Sanofi (NASDAQ:SNY)
Aigen Investment Management LP acquired a new position in Sanofi (NASDAQ:SNY – Get Rating) in the third quarter, HoldingsChannel.com reports. The fund acquired 64,773 shares of the company's stock, valued at approximately $2,463,000.
A number of other large investors have also modified their holdings of SNY. FMR LLC raised its position in shares of Sanofi by 1.3% during the 2nd quarter. FMR LLC now owns 18,715,053 shares of the company's stock worth $936,314,000 after purchasing an additional 234,158 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Sanofi by 162.9% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 17,244,354 shares of the company's stock worth $862,735,000 after purchasing an additional 10,684,509 shares during the last quarter. Invesco Ltd. raised its position in shares of Sanofi by 2.3% during the 1st quarter. Invesco Ltd. now owns 5,077,848 shares of the company's stock worth $260,697,000 after purchasing an additional 112,404 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its position in shares of Sanofi by 276.1% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 3,362,112 shares of the company's stock worth $172,611,000 after purchasing an additional 2,468,271 shares during the last quarter. Finally, Lazard Asset Management LLC raised its position in shares of Sanofi by 0.8% during the 1st quarter. Lazard Asset Management LLC now owns 3,321,721 shares of the company's stock worth $170,536,000 after purchasing an additional 25,457 shares during the last quarter. Institutional investors and hedge funds own 10.04% of the company's stock.
Get Sanofi alerts:Sanofi Stock Performance
Sanofi stock opened at $45.86 on Tuesday. The firm has a 50 day simple moving average of $47.91 and a 200-day simple moving average of $43.28. Sanofi has a 1-year low of $36.91 and a 1-year high of $58.10. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.29 and a quick ratio of 0.34. The stock has a market cap of $115.64 billion, a price-to-earnings ratio of 16.21, a price-to-earnings-growth ratio of 1.07 and a beta of 0.56.
Analysts Set New Price Targets
SNY has been the subject of several research analyst reports. Morgan Stanley restated an "overweight" rating on shares of Sanofi in a research report on Tuesday, December 13th. TheStreet upgraded shares of Sanofi from a "c+" rating to a "b-" rating in a report on Friday, December 2nd. StockNews.com started coverage on shares of Sanofi in a report on Wednesday, October 12th. They issued a "strong-buy" rating for the company. Barclays cut their price objective on shares of Sanofi from €105.00 ($112.90) to €85.00 ($91.40) and set an "equal weight" rating for the company in a report on Friday, October 14th. Finally, The Goldman Sachs Group started coverage on shares of Sanofi in a report on Friday, December 16th. They issued a "buy" rating for the company. Five analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $102.88.About Sanofi
(Get Rating)
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities.
Further Reading
- Get a free copy of the StockNews.com research report on Sanofi (SNY)
- Why Is Wall Street Loving Amazon So Much?
- Want to Invest in ChatGPT? Then Buy Microsoft Stock
- Anhui Conch: Opportunity With Cement Solid Cash Flows
- Is Merck Stock a Buy After Its Post-Earnings Sell-Off?
- Is Biotech Immunocore About To Make A 25% Price Move?
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY – Get Rating).
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.
Aigen Investment Management LP acquired a new position in Sanofi (NASDAQ:SNY – Get Rating) in the third quarter, HoldingsChannel.com reports. The fund acquired 64,773 shares of the company's stock, valued at approximately $2,463,000.
Holdingschannel.com报道，艾根投资管理有限责任公司在第三季度收购了赛诺菲（纳斯达克股票代码：SNY — Get Ratings）的新职位。该基金收购了该公司64,773股股票，价值约为246.3万美元。
A number of other large investors have also modified their holdings of SNY. FMR LLC raised its position in shares of Sanofi by 1.3% during the 2nd quarter. FMR LLC now owns 18,715,053 shares of the company's stock worth $936,314,000 after purchasing an additional 234,158 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in shares of Sanofi by 162.9% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 17,244,354 shares of the company's stock worth $862,735,000 after purchasing an additional 10,684,509 shares during the last quarter. Invesco Ltd. raised its position in shares of Sanofi by 2.3% during the 1st quarter. Invesco Ltd. now owns 5,077,848 shares of the company's stock worth $260,697,000 after purchasing an additional 112,404 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its position in shares of Sanofi by 276.1% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 3,362,112 shares of the company's stock worth $172,611,000 after purchasing an additional 2,468,271 shares during the last quarter. Finally, Lazard Asset Management LLC raised its position in shares of Sanofi by 0.8% during the 1st quarter. Lazard Asset Management LLC now owns 3,321,721 shares of the company's stock worth $170,536,000 after purchasing an additional 25,457 shares during the last quarter. Institutional investors and hedge funds own 10.04% of the company's stock.
其他一些大型投资者也修改了他们持有的SNY。FMR LLC在第二季度将其在赛诺菲的股票头寸提高了1.3％。FMR LLC在上个季度又购买了234,158股股票后，现在拥有该公司18,715,053股股票，价值936,314,000美元。Price T Rowe Associates Inc.总经理在第二季度将其在赛诺菲股票中的头寸提高了162.9％。Price T Rowe Associates Inc. MD在上个季度又购买了10,684,509股股票后，现在拥有该公司17,244,354股股票，价值862,735,000美元。景顺有限公司在第一季度将其在赛诺菲的股票头寸提高了2.3％。景顺有限公司在上个季度又购买了112,404股股票后，现在拥有该公司5,077,848股股票，价值260,697,000美元。Arrowstreet Capital Limited Partnership在第一季度将其在赛诺菲的股票头寸提高了276.1％。Arrowstreet Capital Limited Partnership在上个季度又购买了2468,271股股票后，现在拥有该公司3,362,112股股票，价值172,611,000美元。最后，拉扎德资产管理有限责任公司在第一季度将其在赛诺菲的股票头寸提高了0.8％。拉扎德资产管理有限责任公司在上个季度又购买了25,457股股票后，现在拥有该公司3,321,721股股票，价值170,536,000美元。机构投资者和对冲基金拥有该公司10.04％的股票。
Sanofi Stock Performance
赛诺菲股票表现
Sanofi stock opened at $45.86 on Tuesday. The firm has a 50 day simple moving average of $47.91 and a 200-day simple moving average of $43.28. Sanofi has a 1-year low of $36.91 and a 1-year high of $58.10. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.29 and a quick ratio of 0.34. The stock has a market cap of $115.64 billion, a price-to-earnings ratio of 16.21, a price-to-earnings-growth ratio of 1.07 and a beta of 0.56.
赛诺菲股票周二开盘价为45.86美元。该公司的50天简单移动平均线为47.91美元，200天简单移动平均线为43.28美元。赛诺菲创下1年低点36.91美元，1年高点58.10美元。该公司的债务与权益比率为0.22，流动比率为1.29，速动比率为0.34。该股的市值为1156.4亿美元，市盈率为16.21，市盈增长率为1.07，beta值为0.56。
Analysts Set New Price Targets
分析师设定了新的价格目标
About Sanofi
关于赛诺菲
(Get Rating)
（获取评分）
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities.
赛诺菲从事药品的研究、生产和分销。它通过以下业务部门运营：制药、消费者医疗保健和疫苗。制药板块包括以下全球特许经营的商业运营：专业护理、糖尿病和心血管、成熟的处方药和仿制药以及研究、开发和生产活动。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Sanofi (SNY)
- Why Is Wall Street Loving Amazon So Much?
- Want to Invest in ChatGPT? Then Buy Microsoft Stock
- Anhui Conch: Opportunity With Cement Solid Cash Flows
- Is Merck Stock a Buy After Its Post-Earnings Sell-Off?
- Is Biotech Immunocore About To Make A 25% Price Move?
- 免费获取 StockNews.com 关于赛诺菲（SNY）的研究报告的副本
- 为什么华尔街如此喜欢亚马逊？
- 想投资 ChatGPT 吗？然后买入微软股票
- 安徽海螺集团：水泥现金流带来的机遇
- 默克股票在盈利后抛售后是否值得买入？
- Biotech Immunocore 即将价格上涨 25% 吗？
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY – Get Rating).
想看看还有哪些对冲基金持有 SNY 吗？ 访问Holdingschannel.com，获取赛诺菲（纳斯达克股票代码：SNY — 获取评级）的最新13F文件和内幕交易。
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.
接收赛诺菲日报的新闻和评级 -在下面输入您的电子邮件地址，即可通过Marketbeat.com的免费每日电子邮件时事通讯接收赛诺菲及相关公司最新新闻和分析师评级的简明每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧